Rudolf von Buenau

President & CEO

We are Altavo, the Artificial Voice Company (Dresden, Saxony, Germany). We help voiceless people regain an individual, natural sounding voice of their own. Our unique solution is based on non-invasive radar sensing and AI algorithms. Compared to the standard of care for laryngectomy patients, our approach offers better voice quality, reduces the need for follow-up, and eliminates the complication risk of implants. Our technology is applicable across a range of clinical indications as well as non-medical professional and/or consumer applications.

Therapeutic: ENT

Alucent Biomedical (Salt Lake City, Utah, USA) is a privately held medical technology company focused on transforming the way vascular disease is treated. We are using our proprietary technology, AlucentNVS, to harness the body’s own native structural proteins to promote vascular patency. AlucentNVS is a breakthrough technology being developed in ongoing clinical studies to address two unmet medical needs: (1) treating patients with lower extremity peripheral artery disease (PAD); and (2) promoting successful maturation of arteriovenous fistula (AVF) for patients requiring hemodialysis access. It is the first technology of its kind that is designed to reinforce the vessel wall to promote durable patency - without anything left behind in the vessel.

Therapeutic: Cardiovascular

Guillaume Petit-Pierre

CEO & Co-founder

Today the best option to treat stroke consists in employing the patient vascular system as an access route to deliver a treatment in the brain. Although 410’000 such procedures are carried out every year, current interventional devices do not provide sufficient control to the surgeon resulting in increased risk of complications, increased costs and increased surgery duration. We developed a micro-actuated device allowing to treat vascular diseases with unprecedented accuracy, effectiveness and safety.

Therapeutic: Neurovascular, Cardiovascular and Peripheral

Enrique Vega

CEO & Co-founder

Azalea Vision (Belgium) is developing a smart bionic iris embedded in a contact lens for patients suffering from iris disorders, light sensitivity, and early presbyopia. The smart iris is an autonomous, adaptive light filtering, mimicking a functional iris, embedded inside a contact lens, without need for intra-ocular surgery. The patients keep the control over the therapy to accommodate the functioning of the bionic iris to any evolution of their symptoms or needs during their daily life.

Therapeutic: Ophthalmology, Light Sensitivity, Early Presbyopia

Chris Murphy

Co-founder & CEO

Bluedrop Medical (Galway, Ireland) have developed a remote monitoring solution for the early detection of diabetic foot ulcers. Their device takes the form of a bathroom scales, used in the patient’s home. Thermal and visual data of the soles of the feet is collected and sent to a HIPAA secure cloud for remote analysis using advanced AI-powered software and expert professionals employed by Bluedrop. Communication to the individuals using the device and their healthcare provider occur if any abnormalities are detected.

Therapeutic: Remote Patient Monitoring, Diabetes, Diabetic Foot Ulcer, Wound Care

Peter Bloch

CEO

Bresotec's (Toronto, Ontario, Canada) new apnea diagnosis system is based on a unique approach that delivers a more accurate and easy to use at-home device that relies on measurement of respiratory airflow as its primary means of diagnosis, similar to the in-lab gold standard. Respiratory airflow is the most important measurement used by sleep physicians to diagnose sleep apnea. This system has demonstrated industry leading airflow accuracy, with less than a 2.5% error rate versus the PSG gold standard.

Therapeutic: Diagnostics, Sleep Apnea

Patient compliance is a critical issue in many therapeutic areas. With its ARIS drug-eluting resorbable polymers platform, Dianosic (France) aims at delivering drugs with precision while providing a sustained and controlled released for a long term treatment (6 to 12 months) of chronic diseases such as allergic rhinitis or sinusitis. This new treatment modality will unleash the patient from treatment adherence challenges and has the potential to transform the patient pathway in other verticals, beyond ENT.

Therapeutic: ENT, Drug delivery / Biomaterials / drug-eluting resorbable solutions

Type 1 diabetes mellitus (T1D) is a chronic autoimmune disease that prevents the body from producing insulin naturally. Therefore, the 18 million people with T1D need to take regular doses of insulin to control their blood glucose levels. Fada Medical (Galway, Ireland) are developing a 30 day extended wear infusion set cannula (10 times longer wear time than the current gold standard) to improve the delivery of insulin from an insulin pump.

Therapeutic: Diabetes

Youssef Helwa

CEO & Co-Founder

Company: FluidAI (Kitchener, ON, Canada) is an Artificial Intelligence company focused on using AI to improve patient outcomes enabling data-driven patient recovery. With the use of our Stream™️ Platform, Healthcare Providers can customize the way that patients receive post-operative treatment through predictive insights.

Technology: Strem™️ is the first Artificial Intelligence assistant In post-operative care enabling data driven patient recovery. The system uses a combination of novel hardware (Origin™️) that connects to patients' catheters/drains providing over 10M+ data points a day around the evolution of the patient's biomarkers coupled with a monitor (Delta™️) that enables data visualization.

Therapeutic: Diagnostics, AI, Surgical Intelligence, Surgery, Remote Patient Monitoring, IVD, Preventive Medicine, Precision Care

Maximilien Vermandel

CEO & Co-founder

Hemerion (Lille, France) develops new cancer therapies with a focus on glioblastoma, the most common and aggressive primary brain tumor. Hemerion owns a unique and ground-breaking technology elaborated with neurosurgeons and already evaluated in a first-in-human. This treatment is based on a photosensitizing drug, administered to the patient before surgery, and an exclusive photonic system. This unique drug-device combination therapy selectively destroys cancer cells, in areas inaccessible to classic surgery and without harming healthy tissues.

Therapeutic: Oncology, Minimally Invasive Solution for GBM

Carolina Aguilar

CEO

Neuro and bio electronic implants could be the side-effect free, and faster alternative to typical medicine INBRAIN (Barcelona, Spain) therefore belongs to the bioelectronics field, implants that decode and modulate different brain & nerve targets depending on the indication using signal processing theory with the objective to modulate central and peripheral nervous networks to alleviate neurological disorders. We are developing a graphene based platform that powered by machine learning have the capability of reading single neuro cells at a resolution never seen before, detecting therapy specific biomarkers and triggering adaptive responses for increased outcomes in personalised neurological therapies in a minimally invasive way Additionally INNERVIA Bioelectronics is a subsidiary developing high resolution VNS therapies together with Merck.

Therapeutic: Neuromodulation-Neurostimulation, Brain Computer Interface (BCI)

Todor Jeliaskov

President & CEO

inHEART’s (Pessac, France, and Cambridge, Massachusetts) web-based, cloud-based, AI-based SaaS leverages medical images and electrocardiograms to deliver a digital twin of the patient’s heart, allowing physicians to individualize and optimize each patient’s treatment strategy and ablate with greater efficiency and efficacy. The company has gathered clinical data, received a CE mark and 510(k) clearance, and is rapidly growing its user base in Europe, the US, and Australia. In addition, inHEART uses its vast amount of annotated clinical data to develop powerful predictive AI to assess the risk of sudden cardiac death, stroke, heart attack, and heart failure in large patient populations.

Therapeutic: Cardiac arrhythmia management

Pierre Douette

CEO

Intressa Vascular (Isnes, Belgium) is a clinical stage company developing innovative endovascular treatment approaches to aortic dissection, the most-common life-threatening acute event affecting the aorta. The Allay™ Aortic Stent is a unique multilayer stent designed to provide extensive coverage of the dissection for blood flow recentralization while preserving branch perfusion, in a streamlined procedure with a low risk of complications.

Therapeutic: Cardiovascular

LaNua Medical (University College Dublin, Dublin 4, Ireland) is developing enhanced technological solutions for endovascular procedures. Embolisation procedures involve placement of occlusive devices/materials to block blood flow. Initially developed to treat internal bleeding, complexity and indications have grown, with embolization increasingly performed for cancerous and benign tumour treatment. The GateKeeper Occlusion device is being designed to enable accurate and swift embolisation, while maintaining distal through-and-through access, to allow visualisation of surrounding vasculature and lead to improved distal treatment.

Therapeutic: Interventional, Oncology

Locate Bio (Nottingham, Nottinghamshire, UK) uses two separate drug delivery technologies to achieve breakthrough performance from existing drug molecules. With outstanding preclinical data, LDGraft is moving into human clinical studies in 2023 for the treatment of chronic low back pain. CognitOss has also shown a significant improvement in performance compared to the current market leader in treating prothetic joint biofilm infections. Both products have the potential to become the class leaders in their respective categories.

Therapeutic: Drug Delivery

Sjaak Deckers

CEO

Microsure (Eindhoven, the Netherlands) develops a unique robot for open microsurgery, allowing surgeons to continue using their own microinstruments. It has an accuracy that exceeds human precision, combined with a large dexterity allowing a wide range of procedures ranging from free flap transfers, lympho-venous anastomores to micro-neuro-anastomoses or digital nerve repairs. The technology is validated in several clinical studies using a prototype system, we are currently finalizing the first product, MUSA-3.

Therapeutic: Robotics

OxiFlow™️ by Oxford Endovascular (Oxford) is a novel, next generation flow-diverter, using ‘Origami Engineering’, that diverts blood flow away from intracranial aneurysms at risk of rupture. It places more accurately and safely than existing devices, opens reliably even in the most tortuous situations unlike the existing state-of-the-art, reducing the risk of adverse events. It conforms better to blood vessels, making more patients treatable and has the capability to become the market leading device.

Therapeutic: Neurovascular, Brain Aneurysm treatment

Laurence Blizianu

CBO

PreciHealth (Neuchâtel, Switzerland) is offering the best system for Diagnosis based on Self Capillary Blood collection integrated with an AI based digital solution for patient authentication, real-time guidance and certification. The company's vision is to revolutionize the way people undergo blood tests by introducing an innovative Self Blood Collection System that can be done at home, clinics, labs or anywhere.

Therapeutic: Diagnostics, Auto-injectors and self vaccination solution

Positrigo's (Zurich, Switzerland) vision is to image everyone. Offering innovative solutions for providing functional brain positron emission tomography scans to the masses, our first focus is the early detection of Alzheimer's Disease. With the advent of preventive treatments on the horizon, an early and reliable diagnostic technique is of utmost importance. This is where Positrigo will provide a solution with which healthcare providers can make more functional brain scans on the same space for lower cost than today.

Therapeutic: Imaging

Edvardas Satkauskas

CEO

Inovativy Medicina (Lithuania) has developed a robotic system for endovascular procedures - Sentante – a smart, sensory, teleoperated robot system which allows the procedure to be performed remotely, from a different room, thus protecting physicians from harmful X-rays and opening up tele-surgery possibilities. The system senses operators’ movements and provides close to natural haptic force feedback - physicians can feel the catheter and guidewire resistance just as if they were standing near the patient.

Therapeutic: Robotics

Dr. Christian Sternitzke

Co-founder & Co-CEO

TEDIRO (Ilmenau/Thuringia, Germany) stands for therapy and diagnostics robots. We develop a versatile mobile robotic platform for running multiple medical apps for highly standardized diagnoses or therapies, making use of computer-vision technology/AI. Our first application addresses patient mobilization by robot-supervised walking exercises for clinical rehabilitation in orthopedics and geriatrics. We develop the apps ourselves but will start building a partner ecosystem to add solutions from partners to scale faster. Our goal is to help clinics handling the staff shortage and increasing costs.

Therapeutic: Robotics

Jeff Amacker

CEO

TibaRay (Santa Clara, California, USA) is an early stage company developing a new Radiation Therapy system that will treat cancer patients in a fraction of a second, resulting in dramatically reduced collateral damage to normal tissue leading to better outcomes. The enabling technological breakthrough that came out of the SLAC National Accelerator Lab and Stanford University Healthcare uniquely positions TibaRay to disrupt this $7B market by curing cancer in a FLASH.

Therapeutic: Oncology

Tjeerd Homsma

CEO

Customized Aneurysm Repair (CAR) by TripleMed (Geleen, the Netherlands) is a breakthrough technology to treat Abdominal Aortic Aneurysms. Using 2 Dog-bone shaped PTA-balloons and AneuFix 2-component PDMS polymer, the complete Aneurysm Sac is filled with an in-situ curing flexible implant. CAR offers a Simple, Durable and Cost-effective solution to treat AAA, addressing the remaining clinical needs of current EndoVascular Aneurysm Repair treatments using Endografts.

Therapeutic: Cardiovascular, Aortic Aneurysm

Finbar Dolan

Founder & CEO

VERSONO Medical's (Parkmore West Business Park, Galway, H91HP4F) mission is Transforming Endovascular Treatment of Complex and Calcific CTO's with its FastWire Endovascular Technology Platform.

Therapeutic: Cardiovascular, Peripheral Vascular / Endovascular Devices

ViCentra (Rijnzathe 6, 3454PV Utrecht, the Netherlands) markets Kaleido, the world’s smallest and lightest insulin pump. Kaleido is waterproof, available in 10 bright colours and is available both as a manual and an automated insulin delivery system. CE marked since 2016 and is commercially available in select European countries. ViCentra was founded in 2013 and is backed by EQT Ventures, INKEF Capital, Health Innovations, Invest-NL, Partners in Equity and Kreos Capital

Therapeutic: Diabetes

Toon Overbeeke

Co-founder & CEO

Vitestro’s (Utrecht, the Netherlands) autonomous venipuncture device meets a largely unmet need of solving significant healthcare staff shortages partly caused by a labor intensive and unautomated blood drawing procedure performed ~10 billion times p.a. globally. Our device is state of the art technology using AI and robotics, clinically validated through >1,500 blood draws. With our team of >40 people and backed by Sonder Capital, we are in the final stage of development and expect to be on the European market in 2024.

Therapeutic: Robotics, Diagnostics